Good Syndrome (Thymoma with Immunodeficiency): Comprehensive Research Report

1. Disease Information

Overview. Good syndrome (GS) — also called thymoma-associated immunodeficiency or thymoma with immunodeficiency — is a rare, adult-onset combined (B-cell and T-cell) primary immunodeficiency occurring in patients with a thymoma. It was first described by Robert A. Good in 1954–1955 after he noted the co-occurrence of thymoma and hypogammaglobulinemia. GS is now recognized by the WHO/International Union of Immunological Societies (as of 1999) as a distinct primary immunodeficiency, separate from common variable immunodeficiency (CVID), despite frequent misdiagnosis as CVID (PMC12647230; PMC8019250).

Key identifiers: - MONDO: MONDO:0015696 - Orphanet: ORPHA169105 (orpha.net) - ICD-10: D81.8 (Other combined immunodeficiencies) - ICD-11: 4B40.2 - OMIM: No dedicated OMIM entry exists (it is an acquired, not classically Mendelian, disorder) - MeSH/synonyms: Thymoma with immunodeficiency; thymoma-associated hypogammaglobulinemia; Good's syndrome; thymoma-associated combined immunodeficiency

Nature of evidence base. Because GS is exceedingly rare, the literature is dominated by individual case reports and small retrospective/cross-sectional case series pooled into systematic reviews, plus (as of 2023–2024) the first prospective longitudinal cohort study. There is essentially no large-scale EHR/claims-based epidemiology; most quantitative "prevalence" figures trace back to aggregated case counts rather than population registries.

2. Etiology

Primary causal factor. GS requires the essentially simultaneous presence of a thymic epithelial tumor (thymoma) and acquired hypogammaglobulinemia with B-cell deficiency. There is no known Mendelian/germline genetic cause; it is an acquired (paraneoplastic-like) adult-onset immunodeficiency, distinguishing it from inherited agammaglobulinemias (e.g., XLA) and most forms of CVID.

Genetic risk factors (somatic, not germline): - Thymomas — especially WHO types A and AB, which predominate in GS — very frequently carry a recurrent somatic missense mutation in GTF2I (encoding transcription factor TFII-I), invariably p.L424H. This mutation is found in 82% of type A and 74% of type AB thymomas in large series (Nature Genetics, PMC7466068; PMID:37671056). - A mouse model of the human thymoma-associated GTF2I mutation shows that mutant TFII-I impairs thymic epithelial progenitor differentiation, producing aberrant thymic architecture and reduced thymopoietic activity, particularly of the medullary compartment (PMID:36175547; Communications Biology, PMC9522929) — a plausible mechanistic link between the thymoma's driver mutation and disrupted central tolerance/thymopoiesis. - A dedicated somatic variant profiling study of a GS-associated thymoma has been published, though comprehensive GS-specific genomic characterization (as distinct from thymoma genomics generally) remains limited (ScienceDirect S2772613424000039).

No established environmental/lifestyle causal or protective factors have been identified — GS is not linked to toxin exposure, infection, diet, or lifestyle in the literature reviewed. No GWAS, susceptibility-loci, or gene–environment interaction data exist, consistent with its status as a rare acquired tumor-associated condition rather than a polygenic disease.

3. Phenotypes

Immunological/laboratory phenotypes

Table (click to expand)

Feature	Frequency (pooled case series, n≈162)	Notes
Hypogammaglobulinemia	100%	Median IgG ≈332 mg/dL (normal 700–1600 mg/dL); IgG can be as low as ~100 mg/dL
Low IgA	86.0%
Low IgM	92.6%	(Some reports describe normal IgA/high IgM patterns in individual cases)
Absent/low peripheral B cells (CD19+)	95.2%	Often near-complete absence; distinguishes GS from most CVID
Low CD4+ T-cell count	71.3%
Inverted CD4:CD8 ratio	82.5%	e.g., ratio 0.45 vs. normal >1.1 in reported cases
Absent transitional B cells (CD38+CD24+)	Frequently reported	Suggests a B-cell precursor developmental defect
Loss of unswitched/CD21+ B cells, low CD19/CD20, near-absent surface IgD	Frequently reported
Naïve CD8+CD45RA+ T-cell accumulation	Described as a hallmark finding

Source: PMC8185358 (systematic review, 162 patients); PMC5937423; case reports.

Suggested HPO terms: HP:0002850 (Decreased circulating total IgG), HP:0002850-family Ig deficiency terms, HP:0005404 (Hypogammaglobulinemia), HP:0010976 (Abnormal B cell count / B lymphocytopenia), HP:0005400 (CD4 lymphopenia), HP:0002721 (Immunodeficiency), HP:0002960 (Autoimmunity).

Clinical phenotypes (symptoms/signs)

Recurrent sinopulmonary infections (bronchitis, pneumonia, sinusitis) — the most common presentation (~67% of primary infection sites in the pooled series). Frequent pathogens: Pseudomonas aeruginosa, Haemophilus influenzae, Streptococcus pneumoniae.
Opportunistic/invasive infections despite sometimes-normal CD4 counts: cytomegalovirus (CMV) disease/pneumonitis (~24.7% of infections), mucocutaneous and esophageal candidiasis (~16.7%), Pneumocystis jirovecii pneumonia, cryptococcosis and other invasive fungal disease (PMC8636207).
Gastrointestinal disease: chronic diarrhea, malabsorption, and a distinctive graft-versus-host disease (GVHD)-like colitis with villous blunting and active chronic inflammation on histology, in the absence of any transplant — a signature and underrecognized GI phenotype of GS, distinguishing it pathologically from typical CVID enteropathy (PMC12647230).
Mucocutaneous disease: oral lichen planus is a recurrent, relatively distinctive association (~22.9% of autoimmune manifestations) (PMC11323965).
Hematologic autoimmunity: pure red cell aplasia (PRCA) — the single most common autoimmune association, ~31–35% of GS patients.
Neuromuscular autoimmunity: myasthenia gravis — second most common, ~15–28%, sometimes subclinical.
Rarer: pure white cell aplasia, aplastic anemia/bone marrow failure, CD8+ T-cell large granular lymphocyte leukemia, systemic lupus erythematosus-like features, dementia (rare case reports).

Phenotype characteristics

Onset: adult, typically 40–70 years; mean/median age at diagnosis ~57–60 years (range 35–78 in cohort data).
Severity/progression: immunodeficiency is typically progressive over years to decades — the 2024 McGill natural history study (37-year follow-up) documented gradual worsening of B- and T-cell compartments over time, independent of thymectomy (JACI In Practice, PMID:38122866).
Diagnostic delay: mean delay ~3.1 years (median 1 year, range 0–17 years) — reflecting the rarity and overlap with CVID.

Quality of life

No disease-specific validated QoL instrument was identified in the literature; QoL impact is inferred from the burden of recurrent hospitalization for infection, chronic diarrhea, and autoimmune complications, but formal EQ-5D/SF-36 GS-specific data were not found in this search.

4. Genetic/Molecular Information

No causal germline gene. GS is not a monogenic inherited immunodeficiency; there is no HGNC "disease gene" analogous to BTK in XLA.
Somatic driver in the associated thymoma: GTF2I p.L424H missense mutation (HGNC:4661), present in the great majority of type A/AB thymomas that predominate in GS (PMID:37671056; PMC7466068). This is a tumor-somatic, not germline, variant.
Functional consequence: TFII-I is a transcription factor regulating epithelial progenitor cell proliferation/differentiation in the thymus; the mutant form disrupts bipotent thymic epithelial progenitor differentiation and medullary thymic epithelial cell (mTEC) development in mouse models, plausibly impairing central tolerance mechanisms (including AIRE-dependent negative selection) (PMID:36175547).
AIRE dysregulation: Thymomas — including those in GS — have been reported to show reduced AIRE (autoimmune regulator) gene expression, contributing to defective central tolerance and paraneoplastic autoimmunity.
No confirmed modifier genes, epigenetic signatures, or recurrent chromosomal abnormalities specific to GS (as opposed to thymoma biology generally) were identified.
Allele frequency/population data: not applicable — this is a somatic tumor mutation, not a population polymorphism; gnomAD/1000 Genomes data are not relevant.

5. Environmental Information

No dietary, occupational, toxin, or infectious causal exposures for GS itself were identified — the "trigger" is the thymoma, not an external agent. Infections in this section are better understood as consequences (complications) of the immunodeficiency rather than causes; see Phenotypes and Diagnostics sections for the pathogen spectrum (CMV, Pseudomonas, Candida, Pneumocystis jirovecii).

6. Mechanism / Pathophysiology

Causal chain (numbered, with inference flagged)

A thymic epithelial neoplasm arises, in the great majority of GS cases a WHO type A (lymphocyte-poor spindle cell, ~23.5%) or type AB (mixed spindle/lymphocyte-rich, ~50.0%) thymoma, frequently driven by the somatic GTF2I p.L424H mutation → this leads to disruption of normal thymic epithelial architecture.
Mutant TFII-I impairs bipotent thymic epithelial progenitor differentiation, particularly of the medullary lineage → this leads to (inferred, extrapolated from mouse model, PMID:36175547) reduced thymopoietic output and defective AIRE-mediated central tolerance/negative selection.
Disrupted thymic microenvironment and possible bone-marrow-stromal-derived cytokine dysregulation → this leads to (mechanism still incompletely established/hypothesized) impaired B-cell precursor development, evidenced by absence of transitional (CD38+CD24+) B cells and loss of unswitched B-cell subsets.
Progressive peripheral B-cell depletion (near-complete absence of CD19+ cells in >95% of cases) → this leads to failure of plasma-cell differentiation and panhypogammaglobulinemia (low IgG, IgA, IgM).
In parallel, thymic T cells are reported to exert an inhibitory effect on B-cell-mediated immunoglobulin production, and thymoma-associated Treg export defects further destabilize peripheral immune homeostasis → this contributes to both the humoral defect and to loss of self-tolerance.
Concurrently, thymopoietic disruption produces CD4+ T-cell lymphopenia, an inverted CD4:CD8 ratio, and accumulation of naïve CD8+CD45RA+ T cells (proposed hallmark of thymoma-related T-cell dysfunction) → this leads to impaired cell-mediated immunity.
The combined B- and T-cell defect → results in susceptibility to (a) encapsulated/sinopulmonary bacterial pathogens (humoral defect pathway) and (b) viral/fungal/opportunistic pathogens — CMV, Candida, Pneumocystis jirovecii (cellular defect pathway) — clinically manifesting as recurrent infection (in >90% of patients).
Loss of central and peripheral tolerance (from steps 2 and 5) → branches into a distinct autoimmune phenotype: pure red cell aplasia (autoantibody/T-cell mediated marrow suppression of erythroid precursors), myasthenia gravis (anti-acetylcholine-receptor autoimmunity), GVHD-like colitis, and oral lichen planus — occurring in ~51–76% of patients depending on the cohort.
Because the immune defect originates from stem/progenitor-level or established peripheral lymphocyte depletion rather than from the tumor mass itself, thymectomy removes the neoplasm but does not reverse the hypogammaglobulinemia or B-cell aplasia in most patients — the defect is durable/self-perpetuating once established (an important and repeatedly confirmed clinical-mechanistic observation, PMC8185358).

Overall causal status: The Frontiers 2021 review explicitly states the pathophysiology "remains unclear," though it proposes the thymoma "disrupts the balance between host-defense and self-tolerance" (PMC8185358); another review states "many different theories were proposed on the pathogenesis of Good's syndrome but so far none has gained acceptance, making this syndrome still a mystery." Much of the mechanistic chain above (steps 2–5) is therefore inferential/hypothesis-level, built from a combination of a small number of tissue studies (e.g., B-cell depletion demonstrated directly within thymoma tissue — Discover Oncology 2024, showing complete B-cell absence in thymoma tissue of 4/5 GS patients) and mouse GTF2I models, rather than a fully demonstrated human causal pathway.

Molecular pathways/GO terms suggested: - GO:0033077 T cell differentiation in thymus - GO:0002519 natural killer cell tolerance induction / GO:0002377 immunoglobulin production - GO:0030217 T cell differentiation - GO:0042475 odontogenesis (n/a) — not relevant; instead: GO:0048538 thymus development - GO:0002250 adaptive immune response

Cell types (CL terms): - CL:0000236 B cell (depleted) - CL:0000899 Th cell / CL:0000624 CD4-positive, alpha-beta T cell (lymphopenic) - CL:0000625 CD8-positive, alpha-beta T cell (naïve accumulation) - CL:0002293 epithelial cell of thymus / thymic medullary epithelial cell - CL:0000980 plasmablast / CL:0000786 plasma cell (deficient)

Advanced/omics data: Single studies exist profiling "in-depth blood immune profiling of Good syndrome patients" (PMC10684950) and immunological signature studies of thymic epithelial tumor/GS patients (Frontiers 2022), but no large-scale transcriptomic (GEO), proteomic, or single-cell atlas specific to GS was identified — this remains a substantial evidence gap.

7. Anatomical Structures Affected

Primary organ: Thymus (anterior mediastinum) — site of the neoplasm (UBERON:0002370 thymus).
Secondary/systemic involvement:
Bone marrow (erythroid aplasia, occasional pancytopenia) — UBERON:0002371
Lungs/sinopulmonary tract (recurrent infection, bronchiectasis) — UBERON:0002048
Gastrointestinal tract, especially small intestine/colon (GVHD-like colitis, villous atrophy) — UBERON:0000160 (intestine)
Oral mucosa (lichen planus) — UBERON:0003729
Neuromuscular junction (myasthenia gravis) — UBERON:0000151
Skin/soft tissue (infections, ~18% of infection sites)
CNS (rare invasive infection, ~8% of infection sites)
Body systems: immune system, hematologic system, respiratory system, gastrointestinal system, neuromuscular system.
Cellular level: peripheral B lymphocytes and their bone-marrow/thymic precursors; CD4+ and CD8+ T lymphocyte compartments; thymic epithelial cells (neoplastic).
Subcellular: not specifically characterized beyond transcriptional dysregulation (nucleus, via GTF2I/TFII-I).
Laterality: thymoma is typically a solitary anterior mediastinal mass; no laterality preference reported.

8. Temporal Development

Onset: adult-onset, typically 40–70 years (mean/median ~57–60 years); a large McGill cohort recorded median age at thymoma diagnosis of 57.5 years (range 35–78). GS does not occur in childhood, unlike many primary immunodeficiencies and unlike a subset of CVID.
Onset pattern: insidious — recurrent infections often precede or coincide with thymoma detection; diagnosis is frequently delayed (mean 3.1 years, median 1 year, up to 17 years).
Progression: The 2024 prospective natural history study (McGill, 8 patients, up to 37 years follow-up) is the first to formally characterize GS as a "progressive adult combined immunodeficiency" — B- and T-cell compartments continue to decline over years/decades even after thymectomy (PMID:38122866).
Disease course pattern: chronic, generally progressive, punctuated by recurrent infectious episodes and, in many patients, later-onset autoimmune complications (autoimmunity often follows the immunodeficiency temporally).
Duration: lifelong once established; no reported spontaneous remission of the immune defect.
Thymoma staging at diagnosis: ~68.2% present at localized (Masaoka stage I–II) disease; ~51.4% are disease-free from the tumor at last follow-up versus ~48.6% with active thymoma disease, and active thymoma is itself an independent poor-prognostic factor (OR 4.157) (PMC8185358).

9. Inheritance and Population

Epidemiology: GS is very rare; fewer than 400 reported cases worldwide, mostly from Europe and Asia. Estimated prevalence 1 in 500,000–700,000. GS is found in roughly 6–11% of thymoma patients.
Inheritance pattern: Not inherited — acquired/sporadic disease; no Mendelian pattern, no penetrance/expressivity concept applies, no reported genetic anticipation, germline mosaicism, founder effect, or consanguinity association.
Sex ratio: approximately equal male:female distribution (no significant sex predominance reported).
Geographic distribution: most reported cases from Europe and Asia, though this may partly reflect reporting/publication patterns rather than true geographic clustering.
Comparative epidemiology (from the French DEFI cohort, 690 adults with primary hypogammaglobulinemia): GS patients (n=21) were diagnosed at a median age of 60 years, versus 35 years for CVID and 34 years for B⁻ CVID — underscoring GS's distinctly late-adult onset (CID 2015).

10. Diagnostics

Minimal diagnostic criteria (used consistently across systematic reviews): presence of both thymoma and hypogammaglobulinemia, typically with absent/decreased B cells in most cases (PMC8185358).

Laboratory/immunologic tests:
Serum immunoglobulins: low IgG (median ~332 mg/dL, can be as low as ~100 mg/dL), low IgA (86%), low IgM (92.6%) — though some cases show a "low IgG/normal IgA/high IgM" pattern.
Flow cytometry: markedly reduced or absent CD19+/CD20+ B cells (as low as single-digit percentages), absent transitional (CD38+CD24+) B cells, reduced CD4+ T cells, inverted CD4:CD8 ratio, naïve CD8+CD45RA+ T-cell predominance.
Serology: poor/absent vaccine-antigen response (isohemagglutinins, tetanus/pneumococcal titers) consistent with functional antibody deficiency.
Imaging: Chest CT demonstrating an anterior mediastinal mass (thymoma); may also show mediastinal/hilar lymphadenopathy, bilateral traction bronchiectasis, and pulmonary nodules from chronic/recurrent infection.
Histopathology: Surgical thymoma specimen classified by WHO histologic subtype (predominantly type A or AB in GS); B-cell depletion can be demonstrated directly in thymoma tissue. GI biopsy in symptomatic patients may show villous blunting and GVHD-like active chronic inflammation, distinguishing the enteropathy from classic CVID-associated nodular lymphoid hyperplasia.
Genetic testing: Not part of routine clinical workup (no germline gene to test); GTF2I mutation status is a research/tumor-genomic finding, not a diagnostic test for GS itself.
Differential diagnosis: Primarily CVID — key distinguishing features are GS's later onset (40–70s vs. childhood/young-adult onset common in CVID), lack of familial clustering, near-total peripheral B-cell absence (vs. CVID's typically normal/mildly reduced B cells with reduced memory subsets), absence of lymphoid hyperplasia, and, critically, presence of thymoma. Other differentials include HIV/AIDS, secondary hypogammaglobulinemia (drug-induced, lymphoproliferative disease), and idiopathic CD4 lymphocytopenia.
Screening: No population screening program exists given rarity; clinical practice recommends checking serum immunoglobulin levels and flow cytometry in any patient with myasthenia gravis or an anterior mediastinal mass, particularly before starting immunosuppressive therapy.

11. Outcome/Prognosis

Mortality: Pooled systematic review of 162 patients found overall mortality of 15.4% (25/162), with 92.0% of deaths attributable to infection. This represents substantial improvement over an earlier systematic review's reported 46.1% mortality, reflecting improved recognition and immunoglobulin replacement access (PMC8185358).
Survival: 10-year overall survival ≈53.7% among patients with documented follow-up.
Independent prognostic factors (multivariate analysis):
Active thymoma disease: OR 4.157 (p=0.023)
Cellular-immunity-related infections: OR 3.324 (p=0.033)
Sinopulmonary infections: OR 14.351 (p=0.003)
CNS infections: OR 6.403 (p=0.029)
Bloodstream infections: OR 6.917 (p=0.012)
Clinical subgroups (cluster analysis) identified three phenotypic clusters with differing infection/autoimmune profiles and prognosis: Cluster 1 (31.5%, cellular-immunity defects, mucosal/CNS infections), Cluster 2 (47.5%, other/unknown immune defect, lower IgG), Cluster 3 (21.0%, humoral/phagocytic defects, sinopulmonary predominance).
Note: Outcomes correlate more strongly with severity of infections and hematologic/autoimmune complications than with thymoma severity per se — i.e., the immunologic phenotype, not the tumor stage alone, drives prognosis.
Complications: recurrent/invasive infection, bone marrow failure/aplasia (gradual, per some reviews), PRCA-related anemia requiring transfusion, myasthenic crisis, chronic malabsorptive enteropathy.

12. Treatment

Immunoglobulin replacement therapy (IVIG/SCIG): the cornerstone of management — lifelong replacement is necessary because thymectomy does not reverse hypogammaglobulinemia. Reported in 78.4% of patients in the pooled series; shown to reduce sinopulmonary infection frequency (PMID:23200552; PMID:29888926). NCIT term: NCIT:C15986 (Pharmacotherapy) with therapeutic agent immune globulin.
Thymectomy: performed in 90.0% of surgical candidates — primarily indicated for oncologic control of the thymoma (and adjunct management of associated myasthenia gravis) rather than for reversing immunodeficiency, since "thymectomy has favorable effects on other parathymic syndromes but is ineffective in improving immunologic deficiencies in Good's syndrome." NCIT: NCIT:C15329 (Surgical Procedure) / thymectomy-specific term.
Antimicrobial prophylaxis: used in only ~17.3% of patients in pooled data — an area of underuse relative to guideline recommendations; targeted prophylaxis (e.g., against Pneumocystis jirovecii, recurrent bacterial sinopulmonary pathogens) is advocated (PMID:29878906).
Immunosuppressive therapy for autoimmune complications: used in ~50.6% of patients with concurrent autoimmunity (e.g., corticosteroids, cyclosporine for PRCA; pyridostigmine/immunosuppression for myasthenia gravis). Case reports describe rituximab (anti-CD20) used successfully for refractory PRCA/myasthenia gravis in thymoma-associated multi-autoimmune syndrome, sometimes combined with tocilizumab (PMID:31472400; PMID:27408396) — used cautiously given pre-existing combined immunodeficiency.
Vaccination: Because of profound humoral (and often cellular) immunodeficiency, live vaccines are generally contraindicated, and non-live vaccines may be poorly immunogenic; passive immunoglobulin replacement is relied upon instead of active immunization for protection.
Supportive care: aggressive treatment of acute infections; monitoring for GI disease (GVHD-like colitis) and hematologic complications; multidisciplinary follow-up (immunology, oncology/thoracic surgery, hematology).
Experimental/advanced therapeutics: No gene therapy, targeted molecular therapy, or GS-specific clinical trials were identified (ClinicalTrials.gov search did not surface GS-specific interventional trials in this review); management remains supportive/replacement-based rather than disease-modifying.
Treatment algorithm summary: (1) diagnose and stage thymoma → (2) thymectomy for oncologic management → (3) lifelong immunoglobulin replacement regardless of surgical outcome → (4) targeted antimicrobial prophylaxis based on infection risk profile → (5) manage autoimmune complications with immunosuppression/rituximab as needed, balanced against infection risk.

13. Prevention

Primary prevention: Not applicable in the classical sense (no known preventable cause); however, prompt recognition of thymoma with early immunologic screening (immunoglobulins + flow cytometry) may allow earlier initiation of protective measures.
Secondary prevention: Early diagnosis of thymoma (often incidental on chest imaging) combined with immunologic workup before immunosuppressive therapy is initiated (e.g., before treating presumed isolated myasthenia gravis) can identify GS early and avoid inappropriate immunosuppression.
Tertiary prevention: Immunoglobulin replacement and antimicrobial prophylaxis to reduce infection-related morbidity/mortality; regular hematologic monitoring for PRCA/marrow failure; GI symptom surveillance for GVHD-like colitis.
Immunization strategy: Passive protection via IVIG/SCIG substitutes for active vaccination; live vaccines avoided.
Genetic counseling: Not applicable — GS is acquired/sporadic, not heritable.
Public health relevance: Minimal, given extreme rarity; no population-level screening programs exist.

14. Other Species / Natural Disease

Dogs (Canis lupus familiaris, NCBITaxon:9615): Thymoma is a recognized canine neoplasm, and canine paraneoplastic syndromes include hypogammaglobulinemia analogous to human Good syndrome, alongside myasthenia gravis, hypercalcemia, and other autoimmune disease (occurring in an estimated 20–40% of dogs with thymoma). This thymoma-associated hypogammaglobulinemia is explicitly described in the veterinary literature as "Good syndrome" in dogs, representing a natural, spontaneously occurring comparative model (PMC5989270; AVMA JAVMA 243:1448).
Cats: Thymoma-associated myasthenia gravis and paraneoplastic syndromes are also documented, though hypogammaglobulinemia specifically is less well characterized than in dogs.
Comparative biology: The naturally occurring canine disease shares the core features (thymoma + acquired antibody deficiency + autoimmune paraneoplastic phenomena) but formal comparative pathology/mechanistic studies bridging dog and human GS are limited.
Zoonotic potential: None — GS is not a transmissible/infectious disease in either species.

15. Model Organisms

No dedicated animal model exists that fully recapitulates human Good syndrome (i.e., an induced thymoma + combined immunodeficiency model). This is an important gap.
Closest genetic model: A mouse model expressing the human thymoma-associated GTF2I p.L424H mutation in thymic epithelium demonstrates impaired thymic epithelial progenitor differentiation and reduced thymopoietic activity, reproducing the upstream thymic-developmental defect implicated in GS pathogenesis, though this model targets thymoma biology broadly rather than GS's immunodeficiency/autoimmunity phenotype specifically (PMID:36175547; Communications Biology, PMC9522929).
Natural (non-induced) model: Companion dogs with spontaneous thymoma and acquired hypogammaglobulinemia represent the best available naturally occurring comparative model, useful for studying spontaneous thymoma-associated humoral immunodeficiency, though systematic mechanistic study in this population is limited.
Cell/tissue-based models: Direct study of resected human thymoma tissue (immunohistochemistry/flow cytometry showing B-cell absence within the tumor microenvironment) has served as a quasi-model system for understanding local immune dysregulation (Discover Oncology 2024).
Applications/limitations: Existing models can address thymic epithelial developmental biology (via GTF2I mouse models) but cannot yet model the peripheral B-cell aplasia, progressive T-cell dysfunction, or autoimmune complications (PRCA, myasthenia gravis, GVHD-like colitis) that define the clinical syndrome — representing a significant unmet need for a translational GS model.

Summary of Key Evidence Gaps (for curation purposes)

Mechanistic pathway from thymoma → B-cell aplasia is not established — multiple reviews explicitly state the pathogenesis is unresolved; curated pathophysiology nodes should be flagged with appropriate hedging/hypothesis status rather than presented as confirmed causal biology.
No GS-specific transcriptomic/proteomic/single-cell atlas exists.
No dedicated GS animal model exists; the GTF2I mouse model addresses only the upstream thymic-developmental step.
Quantitative epidemiology rests on pooled case reports/series rather than population-based registries — prevalence estimates (1/500,000–700,000) should be treated as rough.
OMIM has no dedicated entry; MONDO:0015696 and ORPHA:169105 are the primary stable identifiers.

Sources

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Table (click to expand)

Outcome	Count
References checked	28
Resolved	28
Unresolved (possible confabulation)	0
Unverifiable	0
Quoted claims checked	2
Quoted claims found in source	1
Quoted claims not found in source	1
References weighed for topical relevance	28
On topic	24
Off topic	0

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

PMC:PMC8185358 (abstract only): "disrupts the balance between host-defense and self-tolerance"
Text part not found as substring: 'disrupts the balance between host-defense and self-tolerance' (note: only abstract available for PMID:34113351, full text may contain this excerpt)

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Table (click to expand)

Outcome	Count
Terms checked	32
Resolved	30
Unresolved (possible confabulation)	0
Obsolete	0
Unverifiable	2
Terms whose name was checked	1
Terms named correctly	1
Terms named as a different term	0

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA.

30 of 32 terms resolved to a current term; the rest could not be looked up either way.